Zobrazeno 1 - 10
of 390
pro vyhledávání: '"Tetsuji, Naka"'
Autor:
Koji Saito, MD, Minoru Fujimoto, MD, PhD, Eiji Funajima, MSc, Satoshi Serada, PhD, Tomoharu Ohkawara, MD, Masayuki Ishihara, MD, PhD, Mamiko Yamada, MD, PhD, Hisato Suzuki, MD, PhD, Fuyuki Miya, PhD, Kenjiro Kosaki, MD, PhD, Mikiya Fujieda, MD, PhD, Tetsuji Naka, MD, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 4, Pp 100312- (2024)
Background: In recent years, germline gain-of-function (GOF) mutations in signal transducer and activator of transcription 3 (STAT3) have been identified as a cause of early-onset multiorgan autoimmune diseases with the widespread use of next-generat
Externí odkaz:
https://doaj.org/article/2833f02a68d14eeb94d66e5de4e7ed64
Autor:
Tsukie Kin Tsukuda, Hiroshi Ohnishi, Minoru Fujimoto, Yu Nakatani, Kazufumi Takamatsu, Tetsuji Naka, Akihito Yokoyama
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Progressive fibrosing interstitial lung diseases (PF-ILDs) have a poor prognosis and may be resistant to corticosteroids and/or immunosuppressants, but antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow the det
Externí odkaz:
https://doaj.org/article/c29e9a66f1ee48548423727a2267ec30
Autor:
Natsuka Umezawa, Fumitaka Mizoguchi, Yasuhiro Maejima, Naoki Kimura, Hisanori Hasegawa, Tadashi Hosoya, Minoru Fujimoto, Hitoshi Kohsaka, Tetsuji Naka, Shinsuke Yasuda
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
ObjectivesSerum levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) have been used as useful biomarkers for reflecting the activity of large vessel vasculitides (LVV). However, a novel biomarker that could have a complementary
Externí odkaz:
https://doaj.org/article/c4add4a40e3f430782da5f8606393b89
Autor:
Yoshikazu Nagase, Kosuke Hiramatsu, Masashi Funauchi, Mayu Shiomi, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Ai Miyoshi, Shinya Matsuzaki, Eiji Kobayashi, Toshihiro Kimura, Satoshi Serada, Yutaka Ueda, Tetsuji Naka, Tadashi Kimura
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Endometrial cancer (EC) is a common gynecologic malignancy and patients with advanced and recurrent EC have a poor prognosis. Although chemotherapy is administered for those patients, the efficacy of current chemotherapy is limite
Externí odkaz:
https://doaj.org/article/2b03d3103a2647edbde2abb81acc9041
Autor:
Mizuki Kanda, Satoshi Serada, Kosuke Hiramatsu, Masashi Funauchi, Kengo Obata, Satoshi Nakagawa, Tomoharu Ohkawara, Okinori Murata, Minoru Fujimoto, Fumiko Chiwaki, Hiroki Sasaki, Yutaka Ueda, Tadashi Kimura, Tetsuji Naka
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 35, Iss , Pp 100853- (2023)
Background: Epithelial ovarian cancer (EOC) is a lethal malignant tumor, for which new treatment options are urgently required. Lipolysis-stimulated lipoprotein receptor (LSR) is widely expressed in EOC, and it is associated with poor prognosis. In t
Externí odkaz:
https://doaj.org/article/8aca4d3343e645dd80e48e4e7a9fbf33
Autor:
Eri Munekage, Satoshi Serada, Shigehiro Tsujii, Keiichiro Yokota, Keita Kiuchi, Kenji Tominaga, Minoru Fujimoto, Mizuki Kanda, Sunao Uemura, Tsutomu Namikawa, Taisei Nomura, Ichiro Murakami, Kazuhiro Hanazaki, Tetsuji Naka
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 939-950 (2021)
An antibody-drug conjugate (ADC) is a promising therapeutic modality because selective and effective delivery of an anti-cancer drug is achieved by drug-conjugated antibody-targeting cancer antigen. Glypican 1 (GPC1) is highly expressed in malignant
Externí odkaz:
https://doaj.org/article/5785173f07364c98b9918dddf1a8cf79
Autor:
Yuka Shibata, Hideki Nakajima, Kimiko Nakajima, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Shigetoshi Sano
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 4, Iss 4, Pp 86-88 (2021)
Externí odkaz:
https://doaj.org/article/c090de91f86641428a9bec3566a15ee0
Autor:
YURINA SAITO, TSUYOSHI TAKAHASHI, KOSUKE HIRAMATSU, SATOSHI SERADA, MINORU FUJIMOTO, TOMOHARU OHKAWARA, TAKAHITO SUGASE, TAKAHIKO NISHIGAKI, KOJI TANAKA, YASUHIRO MIYAZAKI, TOMOKI MAKINO, YUKINORI KUROKAWA, KIYOKAZU NAKAJIMA, MAKOTO YAMASAKI, KEN J. ISHII, HIDETOSHI EGUCHI, YUICHIRO DOKI, TETSUJI NAKA
Publikováno v:
Anticancer Research. 43:2425-2432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6b8c63cd078a70cfeb885a012e532f1
https://doi.org/10.21873/anticanres.16410
https://doi.org/10.21873/anticanres.16410
Autor:
Ryugo Teranishi, Tsuyoshi Takahashi, Yuuki Obata, Toshirou Nishida, Shuichi Ohkubo, Hiromi Kazuno, Yurina Saito, Satoshi Serada, Minoru Fujimoto, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Seiichi Hirota, Tetsuji Naka, Hidetoshi Eguchi, Yuichiro Doki
Publikováno v:
International Journal of Cancer. 152:2580-2593
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0e8b8c3476a104a370524caaa8b1c6f
https://doi.org/10.1002/ijc.34461
https://doi.org/10.1002/ijc.34461
Autor:
Daiki Kato, Tomonori Yaguchi, Takashi Iwata, Yuki Katoh, Kenji Morii, Kinya Tsubota, Yoshiaki Takise, Masaki Tamiya, Haruhiko Kamada, Hiroki Akiba, Kouhei Tsumoto, Satoshi Serada, Tetsuji Naka, Ryohei Nishimura, Takayuki Nakagawa, Yutaka Kawakami
Publikováno v:
eLife, Vol 9 (2020)
Current xenogeneic mouse models cannot evaluate on-target off-tumor adverse effect, hindering the development of chimeric antigen receptor (CAR) T cell therapies for solid tumors, due to limited human/mouse cross-reactivity of antibodies used in CAR
Externí odkaz:
https://doaj.org/article/d030ebf95bdf404e87e0c8329118623a